摘要
目的探讨莫西沙星与阿奇霉素在慢性支气管炎急性发作(AECB)治疗中的应用效果。方法选取2016年4月—2017年8月于海门市第四人民医院接受治疗的AECB患者80例,随机分为观察组与对照组,40例/组。对照组给予阿奇霉素治疗,观察组给予莫西沙星治疗,对比两组临床疗效、治疗前后血清白细胞介素6(IL-6)浓度及不良反应发生情况。结果观察组治疗总有效率为95.00%,对照组治疗总有效率为75.00%,组间比较差异有统计学意义(χ~2=6.275,P<0.05);观察组治疗后IL-6浓度(44.78±2.43)pg/mL,低于对照组的(56.93±3.24)pg/mL,差异有统计学意义(t=18.974,P<0.05);观察组不良反应发生率为7.50%,低于对照组的25.00%,差异有统计学意义(χ~2=4.501,P<0.05)。结论与阿奇霉素相比,莫西沙星治疗AECB的临床效果较好,安全性高,可作为AECB患者首选药物。
Objective To study the application effect of moxifloxacin and azithromycin in treatment of acute attack of chronic bronchitis. Methods 80 cases of AECB patients treated in our hospital from April 2016 to August 2017 were selected and randomly divided into two groups with 40 cases in each, the control group were treated with azithromycin, while the observation group were treated with moxifloxacin, and the clinical curative effect, 6 （IL-6） concentration and occurrence of adverse reactions before and after treatment were compared between the two groups. Results The total treatment effeetive rate in the observation group and in the eontrol group was respeetively 95.00% and 75.00%, and the differenee was statistieally signifieant （χ2=6.275, P〈 0.05）; after treatment, the IL-6 eoneentration in the observation group was lower than that in the control group, [（44.78±2.43）pghnL vs （56.93±3.24）pg/mL], and the difference was statistically significant （t=18.974, P〈0.05）; the incidence rate of adverse reactions in the observation group was lower than that in the control group （7.50% vs 25.00%）, and the difference was statistically significant （χ2=4.501, P〈0.05）. Conclusion The clinical effect of oxifloxacin in treatment of AECB is better than that of azithromycin, with high safety, which can be used as the first choice drug of AECB patients.
作者
顾永军
GU Yong-jun(Department of Internal Medicine,Haimen Fourth People＇s Hospital,Haimen,Jiangsu Province,226100 China)
出处
《系统医学》
2018年第18期73-74,77,共3页
Systems Medicine
